A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities (NCT06672939)
Efficacy, Safety, and Pharmacokinetics of Orforglipron Once Daily Oral Versus Placebo in Adolescent Participants Who Have Obesity, or Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (ADVANCE-ATTAIN-ADOLESCENTS)
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months. Participants who have completed the primary PW01 study (including the 4-week safety follow-up period) will have the opportunity to receive an additional 156 weeks of treatment with orforglipron as well as continuing the lifestyle intervention.
Who can join: Review the eligibility criteria below.
Location: Carey Chronis MD Pediatric, Infant and Adolescent Medicine — Oxnard, California
Age range: 12 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (34 Sites)
Showing the first 25 of 34 sites.
- Carey Chronis MD Pediatric, Infant and Adolescent Medicine — Oxnard, California
- Stamford Therapeutics Consortium — Stamford, Connecticut
- Children's Healthcare of Atlanta - Center for Advanced Pediatrics — Atlanta, Georgia
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
- Velocity Clinical Research — Lafayette, Louisiana
- Sundance Clinical Research — St Louis, Missouri
- Lucas Research, Inc. — Morehead City, North Carolina
- Childrens Hospital of Pittsburgh — Pittsburgh, Pennsylvania
- Vanderbilt Health One Hundred Oaks — Nashville, Tennessee
- Dynamed Clinical Research, LP d/b/a DM Clinical Research — Houston, Texas
- La Providence Pediatrics Clinic - Chemidox Clinical Trials — Houston, Texas
- Martin Diagnostic Clinic — Tomball, Texas
- Shamir Medical Center — Beer Jacob,
- Shaare Zedek Medical Center — Jerusalem,
- Sheba Medical Center — Ramat Gan,
- Azienda Ospedaliero Universitaria Meyer — Florence,
- Azienda Ospedaliero Universitaria Maggiore della Carità — Novara,
- Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento — Verona,
- Saitama Medical University Hospital — Iruma-Gun,
- Isesaki Municipal Hospital — Isesaki-shi,
- University Hospital,Kyoto Prefectural University of Medicine — Kawaramachidori, Kamigyo-ku, Kyoto-city,
- Tokyo Medical Center — Meguro-Ku,
- Shiga General Hospital — Moriyama,
- Nara Prefecture General Medical Center — Nara,
- Osaka City General Hospital — Osaka,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Obesity
- Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools — Tampa, Florida
- SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity — Tucson, Arizona
- Piloting a Patient Navigator Program for Weight Loss — Philadelphia, Pennsylvania
- Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) — Mesa, Arizona
- Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects — Orlando, Florida
- Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans — Pittsburgh, Pennsylvania
Explore by condition: All Obesity clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.